Aged serum

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab

Cells1

Outcomes

Angiogenesis

upin human cells1

1 study

Aged serum increases angiogenesis in human cells.
“The combination of aged serum and APP/PSEN1 mutations also resulted in an increase in adhesion of THP-1 neutrophil-like cells, and an increase in sprout length in an angiogenesis assay.”
Cellswith APP/PSEN1 mutationsbrain microvascular endothelial cells
Mutations associated with Alzheimer's disease and aged serum synergistically elicit blood-brain barrier dysfunction in a tissue-engineered model
Fluids and barriers of the CNS16 Feb 2026

Latest

1 in 12 months

Fluids and Barriers of the CNS17 Feb

Mutations associated with Alzheimer's disease and aged serum synergistically elicit blood-brain barrier dysfunction in a tissue-engineered model

Experiments in human cellsMechanisms

Paper

Aged serum

Outcomes

Latest

Mutations associated with Alzheimer's disease and aged serum synergistically elicit blood-brain barrier dysfunction in a tissue-engineered model

Related